IDS and mucopolysaccharidosis: MPS affects CNS; however enzyme replacement therapy is not effective for the brain disease since the therapeutic proteins, such as iduronate-2-sulfatase (IDS) for MPS type II, do not cross the BBB and cannot be delivered to the brain [71, 72].